[
  {
    "cui": "C1654637",
    "cui_name": "androgen independent prostate cancer",
    "incidence_per_100k": 4.8,
    "prevalence_per_100k": null,
    "metric_type": "incidence",
    "total_cases_per_year": 384000,
    "confidence": 0.58,
    "is_subtype": true,
    "parent_disease": "Prostate cancer",
    "reasoning": "Androgen-independent (castrate-resistant) prostate cancer develops in 10-20% of prostate cancer patients. UK primary care database (Enting et al. 2012) reported 3.8 per 100 person-years among all prostate cancer patients. Global estimate extrapolated as ~4.8 per 100,000 based on ~40 per 100k prostate cancer incidence Ã— ~12% CRPC development rate. Data primarily from regional healthcare databases and cohort studies, not global population-level registries.",
    "data_quality": "moderate",
    "geographic_variation": "high",
    "year_specific": false,
    "data_year": 2009,
    "source": "Enting D et al. (2012). Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. Eur Urol. 62(3):434-441; Kirby M et al. (2011). Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 65(11):1180-1192",
    "source_url": "https://pubmed.ncbi.nlm.nih.gov/22910034/",
    "source_type": "literature"
  }
]
